New CFO Appointment: On August 18, 2025, Legend Biotech appointed Carlos Santos as Chief Financial Officer, succeeding interim CFO Jessie Yeung. Santos brings extensive experience from AstraZeneca, Novartis, and Intel, indicating a focus on financial discipline and international operations as the company expands globally.
Impact on Investment Narrative: The appointment of Santos is expected to enhance financial stewardship, although the immediate focus remains on expanding the reach of CARVYKTI, the company's key product. The concentration risk associated with relying on a single product continues to be a significant concern for shareholders.
Financial Performance and Projections
Recent Earnings Update: In the second quarter of 2025, Legend Biotech reported revenues of US$255.06 million but faced a widening net loss of US$125.38 million. The company aims to broaden approvals and market access for CARVYKTI, making disciplined financial management crucial amid ongoing losses and margin pressures.
Future Revenue and Earnings Goals: Legend Biotech projects revenues of $2.3 billion and earnings of $624.8 million by 2028, necessitating a substantial annual revenue growth rate of 43.2% and an increase in earnings of $950.1 million from the current loss of $325.3 million.
Valuation Insights
Fair Value Estimates: Analysts have provided a range of fair value estimates for Legend Biotech, from US$40.82 to US$203.17 per share, reflecting differing views on the company's growth potential and associated risks. The current price suggests a potential upside of 121% to a fair value of $76.66.
Investment Considerations: The wide valuation spread highlights the varying investor perspectives on risks such as product concentration and market competition. The article encourages readers to explore different fair value estimates and consider the potential for significant investment returns.
Research and Analysis Tools
Investment Research Report: Simply Wall St offers a comprehensive research report on Legend Biotech, featuring a visual summary of the company's financial health, which aids in evaluating investment decisions.
Additional Investment Opportunities: The article also mentions other promising investment opportunities, including financially sound penny stocks and companies that have thrived post-COVID, suggesting a proactive approach to portfolio management.
INTC
$37.285+Infinity%1D
Analyst Views on INTC
Wall Street analysts forecast INTC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTC is 35.61 USD with a low forecast of 20.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
34 Analyst Rating
Wall Street analysts forecast INTC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTC is 35.61 USD with a low forecast of 20.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
25 Hold
6 Sell
Hold
Current: 37.510
Low
20.00
Averages
35.61
High
52.00
Current: 37.510
Low
20.00
Averages
35.61
High
52.00
BofA
Neutral -> Buy
upgrade
$500 -> $560
2025-12-11
New
Reason
BofA
Price Target
$500 -> $560
2025-12-11
New
upgrade
Neutral -> Buy
Reason
As previously reported, BofA upgraded Synopsys (SNPS) to Buy from Neutral with a price target of $560, up from $500, arguing that the company's "decent" FY26 guidance derisks China and Intel (INTC) sales and "clears the decks" for "attractive stock catch-up potential" and EPS beats for the next year. The firm raised its FY26 and FY27 EPS estimates following the quarterly report and guidance, the analyst noted.
KGI Securities
Hold
to
Outperform
upgrade
$52
2025-12-09
Reason
KGI Securities
Price Target
$52
2025-12-09
upgrade
Hold
to
Outperform
Reason
KGI Securities upgraded Intel to Outperform from Hold with a $52 price target.
BofA
Underperform -> Neutral
upgrade
$525 -> $500
2025-12-08
Reason
BofA
Price Target
$525 -> $500
2025-12-08
upgrade
Underperform -> Neutral
Reason
As previously reported, BofA upgraded Synopsys (SNPS) to Neutral from Underperform with a price target of $500, down from $525. The FY26 outlook on its upcoming EPS call on December 10 could be "the clearing event" to help address prior concerns around unexplained weakness in its China and the Intel (INTC) IP business as well as high near-term Ansys integration costs, the analyst tells investors. The firm's new FY26 sales and pro-forma EPS estimates are "modestly in line" with consensus, the analyst noted.
Raymond James
initiated
2025-11-20
Reason
Raymond James
Price Target
2025-11-20
initiated
Reason
Raymond James resumed coverage of Intel (INTC) with a Market Perform rating. The company's improved balance sheet and new management provide reasons for hope, but execution risk remains substantial, while Intel lags pure play foundry competitors like TSMC (TSM) and Samsung Foundry on several fronts, the analyst tells investors in a research note. Intel shares are trading well-above median historic earnings multiples, and the firm's sum-of-the-parts model suggests that shares are fairly valued, Raymond James added.
About INTC
Intel Corporation is a global designer and manufacturer of semiconductor products. The Company operates through three segments: Intel Products, Intel Foundry, and All Other. Its Intel Products segment includes Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX). The CCG is bringing together the operating system, system architecture, hardware, and software application integration to enable PC experiences. DCAI delivers workload-optimized solutions to cloud service providers and enterprises, along with silicon devices for communications service providers, network and edge, and HPC customers. NEX helps networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Intel Foundry segment comprises technology development, manufacturing and foundry services. All Other segments include Altera, Mobileye, Other.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
